Last $18.67 USD
Change Today -0.22 / -1.16%
Volume 231.8K
NXTM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 12:02 PM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

nxstage medical inc (NXTM) Snapshot

Open
$18.93
Previous Close
$18.89
Day High
$19.09
Day Low
$18.57
52 Week High
01/27/15 - $19.19
52 Week Low
05/7/14 - $10.69
Market Cap
1.2B
Average Volume 10 Days
472.4K
EPS TTM
$-0.40
Shares Outstanding
62.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NXSTAGE MEDICAL INC (NXTM)

Related News

No related news articles were found.

nxstage medical inc (NXTM) Related Businessweek News

No Related Businessweek News Found

nxstage medical inc (NXTM) Details

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product is the NxStage System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in two segments, System One and In-Center. The System One segment sells and rents the NxStage System One and PureFlow SL dialysate preparation equipment. This segment also sells extracorporeal disposable products, which are primarily used for in-center dialysis treatments for patients with end-stage renal disease (ESRD) in the home and critical care markets. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. NxStage Medical, Inc. markets its products through direct sales force and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

3,200 Employees
Last Reported Date: 03/3/14
Founded in 1998

nxstage medical inc (NXTM) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $437.1K
President
Total Annual Compensation: $308.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $136.3K
President of Nxstage Kidney Care, Inc
Total Annual Compensation: $295.1K
Senior Vice President of Quality Assurance, R...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2013.

nxstage medical inc (NXTM) Key Developments

NxStage Medical, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2014

NxStage Medical, Inc. revised earnings guidance for the fourth quarter and full year ended December 31, 2014. For the fourth quarter of 2014, the company expects to deliver total revenue above $78 million, exceeding the top end of its previously announced guidance range for revenue to be between $74.5 to $76.5 million. This performance is expected to reflect above 18% growth in the Home when compared with the fourth quarter of 2013. The company also expects net loss for the fourth quarter to be at the favorable end of its previously announced guidance range of $5 to $7 million. For the full-year 2014, the company expects to deliver total revenue above $299 million, exceeding the top end of its previously increased guidance range for revenue to be between $296 to $298 million. Annual Home revenue growth for 2014 is expected to be approximately 18%, exceeding the company's previously announced guidance of 15% growth. The company also expects net loss for the full-year 2014 to be at the favorable end of its previously announced guidance range of $24 to $26 million.

NxStage Medical, Inc. Receives FDA Clearance for Home Nocturnal Hemodialysis

NxStage Medical, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its System One™ to perform hemodialysis overnight while the patient is at home sleeping, known as home nocturnal hemodialysis. NxStage's® System One is the first and only hemodialysis machine cleared by the FDA for this indication. Home nocturnal hemodialysis is an important patient option associated with a number of lifestyle and clinical advantages. By doing therapy while sleeping, the patient frees up their day to pursue other activities therefore reducing the overall burden of therapy. A longer, overnight therapy also allows greatly expanded flexibility in dialysis dose and schedule, better enabling physicians to match the dialysis prescription to individual patient needs.

Nxstage Medical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 12:00 PM

Nxstage Medical, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-15-2015 12:00 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jeffrey H. Burbank, Founder, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NXTM:US $18.67 USD -0.22

NXTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $70.98 USD +0.32
Fresenius Medical Care AG & Co KGaA €66.48 EUR +0.71
JMS Co Ltd ¥289.00 JPY +1.00
Nipro Corp ¥1,038 JPY +11.00
View Industry Companies
 

Industry Analysis

NXTM

Industry Average

Valuation NXTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NXSTAGE MEDICAL INC, please visit www.nxstage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.